Science Will Win is an award-winning podcast that takes listeners under the microscope of some the most promising medical innovations, exploring therapies which have the potential to shape the future of healthcare and offer new hope to patients around the world. Through conversations with a diverse line-up of guests, including scientists and experts, patient advocates and, most importantly, patients themselves, each miniseries will focus on a unique healthcare challenge, diving into the fascinating science, policy challenges and potential to transform patients’ lives for the better.
Season 4
Artificial intelligence has the potential to help save millions of lives by accelerating the discovery and development of treatments for humanity’s toughest diseases. Those AI innovations come down to three key factors: data, hardware, and software. Science Will Win Season 4 takes listeners on a journey back in time to learn how each of these three elements got where it is today. Each episode features interviews with historians and cutting-edge researchers, framing these deep historical dives within modern advancements in medical technology. What challenges did science have to overcome to bring us where we are today, the midst of an AI revolution in medicine?
Season 3
Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win explores how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. You'll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance.
Season 2
Host Adam Rutherford returns to explore breakthroughs in oncology, the study and treatment of cancer, and more specifically breast cancer. We hear from the scientists tasked with developing new treatments, oncologists who lead clinical trials and treat patients, and the patients and patient advocates themselves. It’s a groundbreaking time for cancer research, with as many promising possibilities as there are challenges to overcome.
Season 1
Gene therapy is a revolutionary field of science that has the potential to transform lives. It presents this big question; What if we could treat a disease at its root cause, rather than just the symptoms? On the first season of Science Will Win, we look at gene therapy from every angle, speaking to the Pfizer scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy. Listeners hear from a diverse line-up of leading experts on the future-shaping science, challenging policy environment and the personal stories which remain our guiding-light in the search for breakthrough therapies of tomorrow.
Host
Seasons 1 and 2 of Science Will Win are hosted by Adam Rutherford, a geneticist, writer, broadcaster and lecturer at University College London (UCL), U.K. After studying evolutionary biology at UCL, Adam gained a PhD from Great Ormond St Hospital and the Institute of Child Health, London, in the genetics of the developing eye and was also part of the team that identified the first genetic cause of a form of childhood blindness. Since then, Adam spent ten years as an editor for the science journal, Nature, as well as writing and featuring in an array of BBC television, radio and podcast programs.
Season 3 and 4 of Science Will Win is hosted by Jeremiah Owyang. Jeremiah is an entrepreneur, investor, and active professional in the business and technology sectors in Silicon Valley. As a founder, CMO, industry analyst, and public speaker, he is passionate about discovering the next technology trend, explaining it, and helping it become deployed worldwide
This podcast is powered by Pfizer. The information, statements, comments, views and opinions expressed by those guests featured in this podcast are their own and not necessarily representative of the views and opinions of Pfizer Inc.